PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear

Search update by IQWiG confirms results of final report from 2007

2011-01-12
(Press-News.org) It remains an unresolved issue as to whether interstitial brachytherapy has advantages compared to other therapy options in men with localized prostate cancer, nor do newer studies provide proof in this respect. This is the result of a report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 11 January 2011. In this report IQWiG examined whether newer studies challenged the findings of research already completed in 2007. However, it was shown that no relevant new evidence could be obtained from the recent studies. The conclusions of the final report of 2007 therefore remain unchanged.

Comparison of therapy alternatives

Prostate cancer is potentially curable as long as the tumour is still confined to the prostate gland. Several options are available for the treatment of such a localized tumour: besides complete surgical removal of the prostate (prostatectomy) or radiation with an external radiation source (external beam radiotherapy), low-dose-rate (LDR) permanent interstitial brachytherapy offers another therapy option. In this treatment, small radioactive particles are permanently implanted in the prostate via specific needles; these particles enable a local and targeted radiation of the tumour. As prostate tumours either stop growing or grow very slowly in many patients, the fourth option to be considered is a specific form of watchful waiting called active surveillance.

Evidence base is still insufficient

In the research now available, prepared as a rapid report, IQWiG was able to include 20 additional studies, which for the first time also included results of a randomized controlled trial (RCT). However, overall IQWiG still rates the evidence base as insufficient. On the one hand, this is due to the fact that many studies showed deficiencies, so that the results cannot be reliably interpreted. On the other, the studies in part included too few participants and did not last long enough to demonstrate differences between therapies. As the course of early-stage prostate cancer is favourable in most patients (particularly in older ones), differences between therapies in respect of disease progression and survival may only become noticeable after several years.

No robust statements on survival possible

As in the final report of 2007, IQWiG therefore concludes that it has so far not been proven that, compared to the alternative treatment options, brachytherapy is at least equivalent in respect of the (disease-free) survival of patients. This is also due to the fact that PSA-based recurrence-free survival was often analysed as an outcome in the studies. However, this is a non-validated surrogate and in particular is not designed as a surrogate for a comparison between different treatment groups. Therefore no sufficiently robust conclusions can be drawn with regard to advantages or disadvantages of brachytherapy compared to other treatment options. It cannot therefore be definitely precluded that patients who undergo brachytherapy die earlier or have a shorter disease-free survival period.

Against the background of this gap in knowledge, indications that brachytherapy may have certain advantages cannot be reliably classified. In the current rapid report IQWiG also concluded that indications exist that brachytherapy may result in less impairment of sexual function and lower rates of urinary incontinence than the surgical removal of the prostate. Compared to external beam radiotherapy, brachytherapy may also have a less detrimental effect on bowel function. "However, as long as we do not know how reliably brachytherapy works against cancer, this does not suffice to speak of a benefit," says Stefan Lange, IQWiG's Deputy Director.

Moreover, the new studies also provide additional indications of disadvantages of brachytherapy: urinary tract function on the whole, i.e. various voiding disorders, seems to be more strongly impaired with brachytherapy than after removal of the prostate.

G-BA adjourns consultations for outpatient sector

IQWiG was already commissioned by the Federal Joint Committee (G-BA) with the first benefit assessment in December 2004. At that time the Committee wanted to decide whether brachytherapy should in future be available not only in hospitals, but also be performed on an outpatient basis and reimbursed (§135 (1) Social Code Book V). As its benefit was unclear, in December 2009 the G-BA decided to adjourn the consultations, i.e. delay the decision until reliable study results were available.

In June 2009, brachytherapy was also included in the G-BA's agenda for the inpatient sector through a further application for consultation (§ 137c [1] Social Code Book V). As IQWiG's final report was already several years old - and therefore potentially outdated as a basis for decision-making - the G-BA commissioned IQWiG a second time. The aim of this commission for the present search update was to examine whether studies completed in the meantime could change the results of the first IQWiG final report.

Large German study to commence in 2011

In December 2009, the G-BA, which is the supreme body of self-administration in the German health care system, also cleared the way for a large-scale study: with the participation of several institutions, including IQWiG, representatives of the involved specialties, as well as patient representatives, the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) subsequently planned a randomized controlled trial comparing brachytherapy with the three alternative therapy options. The study allows the consideration of patient preferences. It is to commence in 2011 as soon as its final planning and funding have been determined.

Trend-setting solution

"The members of the G-BA have reacted to a health care problem in an exemplary manner here," comments Stefan Lange. "Instead of making decisions on an uncertain evidence base, they have initiated a study that will help to close existing gaps in knowledge. In any event this approach will improve the quality of health care of patients with early-stage prostate cancer."

INFORMATION:

END



ELSE PRESS RELEASES FROM THIS DATE:

Targeting nicotine receptors to treat cognitive impairments in schizophrenia

2011-01-12
Smoking is a common problem for patients with schizophrenia. The increased tendency of patients diagnosed with this disorder is to not only smoke, but to do so more heavily than the general public. This raises the possibility that nicotine may be acting as a treatment for some symptoms of schizophrenia. Nicotine acts through two general classes of brain receptors, those with high and low affinity for nicotine. The low affinity class of nicotinic receptors contains the alpha-7 subunit, which is present in reduced numbers in people with schizophrenia. Two papers published ...

Planck unveils wonders of the Universe

2011-01-12
The first scientific results from Europe's Planck spacecraft featuring the coldest objects in the Universe have today been released. Astronomers at The University of Manchester's Jodrell Bank Observatory played a key role in the worldwide teams searching for an exciting variety of astronomical finds, from massive galaxy clusters to new, unidentified objects. Ranging from within our Galaxy to the most distant reaches of space, Planck is a flagship mission of the UK Space Agency, which funds the UK's involvement in both of Planck's scientific instruments. Astronomers ...

The Starbucks effect: Committed customers don't like logo redesigns, research finds

2011-01-12
The negative reaction to Starbucks' redesigned logo by the company's self-described most loyal customers may be attributable to the strong connection Starbucks' consumers feel toward the brand, according to research co-authored by a professor at Penn State's Smeal College of Business. Karen Winterich, assistant professor of marketing at Smeal, and researchers Michael Walsh of West Virginia University and Vikas Mittal of Rice University recently examined how consumers react to logo redesigns. They found that consumers who are strongly committed to a brand tend to react ...

UT researcher discovers water on moon originated from comets

2011-01-12
Researchers at the University of Tennessee, Knoxville, continue to chip away at the mysterious existence of water on the moon -- this time by discovering the origin of lunar water. Larry Taylor, a distinguished professor in the Department of Earth and Planetary Sciences, was the one last year to discover trace amounts of water on the moon. This discovery debunked beliefs held since the return of the first Apollo rocks that the moon was bone-dry. Then, he discovered water was actually pretty abundant and ubiquitous -- enough so a human settlement on the moon is not ...

Study details how protein made by HPV teams up on and thwarts protective human protein

Study details how protein made by HPV teams up on and thwarts protective human protein
2011-01-12
BETHESDA, Md., Jan. 11, 2011 – An international team of researchers is reporting that it has uncovered new information about human papillomavirus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection. Led by researcher Per Jemth of Uppsala University in Sweden, the collaborators from four institutions detail in the Journal of Biological Chemistry how an offensive protein generated by the sexually transmitted virus handicaps a defensive protein made by the human body. Co-author Neil Ferguson, a biophysicist at University ...

Planck's new view of the cosmic theater

Plancks new view of the cosmic theater
2011-01-12
VIDEO: This animation illustrates the position on the sky of all compact sources detected by Planck during its first all-sky survey and listed in the Early Release Compact Source Catalogue (ERCSC).... Click here for more information. The first scientific results from ESA's Planck mission were released at a press briefing today in Paris. The findings focus on the coldest objects in the Universe, from within our Galaxy to the distant reaches of space. If William Shakespeare ...

Planck space observatory releases first data

2011-01-12
The first scientific results from Europe's Planck spacecraft were released at a press briefing today in Paris. The findings, focusing on the coldest objects in the Universe - both within our galaxy and also out to the most distant reaches of space - include an exciting variety of astronomical finds, from massive galaxy clusters to new, unidentified objects. Planck is a flagship mission of the UK Space Agency, which funds the UK's involvement in both of Planck's scientific instruments. Astronomers from around the UK are now heavily involved in the operation of Planck's ...

Family, friends, social ties influence weight status in young adults

2011-01-12
PROVIDENCE, RI – Does obesity tend to "cluster" among young adults? And if so, what impact does it have on both their weight and weight-related behaviors? That's what researchers from The Miriam Hospital's Weight Control and Diabetes Research Center set out to answer to better understand how social influences affect both weight status and weight loss intentions in this difficult-to-reach age group. According to the study, published online by the journal Obesity, overweight and obese young adults between the ages of 18 and 25 were more likely to have overweight romantic ...

Revealed: Secret businesses which aimed to exploit vaccine fears

2011-01-12
Andrew Wakefield, the disgraced doctor who claimed a link between MMR and autism, planned secret businesses intended to make huge sums of money, in Britain and America, from his now-discredited allegations. The Wakefield scheme is exposed today in the second part of a BMJ series of special reports, "Secrets of the MMR scare", by investigative journalist Brian Deer. Last week we revealed the scientific fraud behind the appearance of a link between the vaccine and autism. Now Deer follows the money. Drawing on investigations and documents obtained under the Freedom of ...

Common painkillers linked to increased risk of heart problems

2011-01-12
The drugs include traditional non-steroidal anti-inflammatory drugs (NSAIDS) as well as new generation anti-inflammatory drugs, known as COX-2 inhibitors. The researchers say that doctors and patients need to be aware that prescription of any anti-inflammatory drug needs to take cardiovascular risk into account. NSAIDs have been the cornerstone of managing pain in patients with osteoarthritis and other painful conditions. In 2004, the COX-2 inhibitor rofecoxib was withdrawn from the market after a trial found that the drug increased the risk of cardiovascular disease. ...

LAST 30 PRESS RELEASES:

A map for single-atom catalysts

What about tritiated water release from Fukushima? Ocean model simulations provide an objective scientific knowledge on the long-term tritium distribution

Growing crisis of communicable disease in Canada in tandem with US cuts

Women get better at managing their anger as they age

Illegal shark product trade evident in Australia and New Zealand

New search tool brings 21% better accuracy for robotics developers

New model extracts sentence-level proof to verify events, boosting fact-checking accuracy for journalists, legal teams, and policymakers

Efficient carbon integration of CO₂ in propane aromatization over acidic zeolites

FPGA-accelerated AI for demultiplexing multimode fiber towards next-generation communications

Vitamin D3 nanoemulsion significantly improves core symptoms in children with autism: A clinical trial

Microfluidic point-of-care device accurately measures bilirubin in blood serum: A pilot study

Amygdalin shows strong binding and stabilizing effects on HER2 receptor: A computational study for breast cancer therapy

Bond behavior of FRP bars in concrete under reversed cyclic loading: an experimental study

Milky Way-like galaxy M83 consumes high-speed clouds

Study: What we learned from record-breaking 2021 heat wave and what we can expect in the future

Transforming treatment outcomes for people with OCD

Damage from smoke and respiratory viruses mitigated in mice via a common signaling pathway

New software tool could help better understand childhood cancer

Healthy lifestyle linked to lower diverticulitis risk, irrespective of genetic susceptibility

Women 65+ still at heightened risk of cervical cancer caused by HPV

‘Inflammatory’ diet during pregnancy may raise child’s diabetes type 1 risk

Effective therapies needed to halt rise in eco-anxiety, says psychology professor

Nature-friendly farming boosts biodiversity and yields but may require new subsidies

Against the odds: Endometriosis linked to four times higher pregnancy rates than other causes of infertility, new study reveals

Microplastics discovered in human reproductive fluids, new study reveals

Family ties and firm performance: How cousin marriage traditions shape informal businesses in Africa

Novel flu vaccine adjuvant improves protection against influenza viruses, study finds

Manipulation of light at the nanoscale helps advance biosensing

New mechanism discovered in ovarian cancer peritoneal metastasis: YWHAB restriction drives stemness and chemoresistance

New study links blood metabolites and immune cells to increased risk of urolithiasis

[Press-News.org] Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear
Search update by IQWiG confirms results of final report from 2007